Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 523.75 INR -1.82% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

P/E
Price to Earnings

28.6
Current
29.6
Median
22.5
Industry
Lower than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
28.6
=
Market Cap
1.2T INR
/
Net Income
43B INR
All Countries
Close
Market Cap P/E
IN
Cipla Ltd
NSE:CIPLA
1.2T INR 28.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
861.2B USD 117.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
3.6T DKK 39.7
US
Johnson & Johnson
NYSE:JNJ
391.9B USD 26.7
US
Merck & Co Inc
NYSE:MRK
269.6B USD 19.6
CH
Roche Holding AG
SIX:ROG
217.6B CHF 18.9
UK
AstraZeneca PLC
LSE:AZN
184.9B GBP 37.3
CH
Novartis AG
SIX:NOVN
196.9B CHF 14.1
US
Pfizer Inc
NYSE:PFE
163.9B USD -63.2
Earnings Growth
IN
Cipla Ltd
NSE:CIPLA
Average P/E: 37.8
28.6
32%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.3
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
39.7
89%
US
Johnson & Johnson
NYSE:JNJ
26.7
-22%
US
Merck & Co Inc
NYSE:MRK
19.6
7 426%
CH
Roche Holding AG
SIX:ROG
18.9
30%
UK
AstraZeneca PLC
LSE:AZN
37.3
175%
CH
Novartis AG
SIX:NOVN
14.1
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -63.2
712%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
25.7
2-Years Forward
P/E
22.9
3-Years Forward
P/E
22.6

See Also

Discover More